IQWiG says Pixuvri provides 'no additional benefit'

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) said in a preliminary benefit assessment that cancer drug Pixuvri pixantrone from Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC) provides "no additional benefit" over patient-individualized care because the company did not submit "suitable" data. Germany's Federal Joint Committee (G-BA) requested that Cell Therapeutics compare Pixuvri -- which is approved to treat multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma -- to patient-individualized care, which the agency said could include at least 11 different therapeutic options. ...